Lannett Receives FDA Approval for Phentermine

December 12, 2007

Lannett Company, Inc. announced it has received approval from the U.S. Food and Drug Administration (FDA) for the company’s supplemental abbreviated new drug application (ANDA) of Phentermine Hydrochloride Capsules 30 mg.
FinanzNachrichten

Adcomm Votes Down ALS Stem Cell Therapy, Debates Clinical Data vs. Personal Data

Lannett Receives FDA Approval for Phentermine

Upcoming Events

GMP Quality Management vSummit 2023: Where Quality Meets Risk

MAGI@home Clinical Research Conference 2023

FDA in 2024: What to Expect in an Election Year

How UDI and UDI Data Can — and Must — Be Used for More Than Just Device Identification

18th Annual FDA Inspections vSummit

Featured Products

FDA, FTC and DOJ Enforcement of Medical Device Regulations

Using Real-World Evidence in Drug and Device Submissions

Featured Stories

Adcomm Votes Down ALS Stem Cell Therapy, Debates Clinical Data vs. Personal Data

Reports Allege Philips Withheld Evidence of Ventilator Malfunctions for 11 Years

Summary Judgment Sought by Boehringer Ingelheim in its IRA Lawsuit

FDA Proposes New Rule on Who has Oversight on Lab Tests

The Revised ICH E8: A Guide to New Clinical Trial Requirements